Published in Eur J Clin Microbiol Infect Dis on August 01, 2007
Pneumococcal conjugate vaccination for older adults: Reply letter to Hollingsworth et al. Hum Vaccin Immunother (2013) 1.54
Estimating rates of carriage acquisition and clearance and competitive ability for pneumococcal serotypes in Kenya with a Markov transition model. Epidemiology (2012) 1.20
Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older. BMC Infect Dis (2010) 1.05
Pneumococcal vaccination of older adults: conjugate or polysaccharide? Hum Vaccin Immunother (2013) 0.96
The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. BMC Infect Dis (2008) 0.94
Cost-effectiveness of a program to eliminate disparities in pneumococcal vaccination rates in elderly minority populations: an exploratory analysis. Value Health (2013) 0.80
Cost of pneumococcal infections and cost-effectiveness analysis of pneumococcal vaccination at risk adults and elderly in Turkey. Hum Vaccin (2011) 0.80
Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakers. Am J Public Health (2012) 0.79
Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil. Hum Vaccin (2011) 0.77
Cost-effectiveness of programs to eliminate disparities in elderly vaccination rates in the United States. BMC Public Health (2014) 0.77
Comparison of dual influenza and pneumococcal polysaccharide vaccination with influenza vaccination alone for preventing pneumonia and reducing mortality among the elderly: A meta-analysis. Hum Vaccin Immunother (2016) 0.75
Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland. Hum Vaccin Immunother (2012) 0.75
Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia. BMC Infect Dis (2014) 0.75
Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA (1996) 14.23
The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med (1991) 6.07
The distinction between cost and charges. Ann Intern Med (1982) 5.93
Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med (2003) 5.60
Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA (2005) 5.29
An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis (2003) 3.93
Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA (1993) 3.31
Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med (2003) 2.87
Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis (2003) 2.75
Primer on medical decision analysis: Part 1--Getting started. Med Decis Making (1997) 2.61
The pneumococcal vaccine after 15 years of use. Arch Intern Med (1994) 2.55
The macro-epidemiology of influenza vaccination in 56 countries, 1997--2003. Vaccine (2005) 2.32
A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med (1984) 2.27
The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med (1988) 2.17
The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med (1999) 2.16
Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis (2006) 2.10
Pneumococcal vaccination for the elderly in The Netherlands? Assessment of the quality and content of available comparative studies. Neth J Med (2004) 2.00
Pneumococcal vaccination in the United States and 20 other developed countries, 1981-1996. Clin Infect Dis (1998) 1.95
Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA (1997) 1.74
Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality. Crit Care Med (2004) 1.58
An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting. Int J Epidemiol (2005) 1.58
Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001-2003. Clin Microbiol Infect (2005) 1.54
[Missing spleen: indication for pneumococcal vaccination]. Ned Tijdschr Geneeskd (2003) 1.53
Invasive pneumococcal disease in England and Wales: vaccination implications. J Infect Dis (2000) 1.42
[Is polysaccharide pneumococcal vaccine effective in adults?]. Ugeskr Laeger (2001) 1.39
Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis (2006) 1.17
Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine (2004) 1.14
Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med (1995) 1.07
The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over. Vaccine (2004) 1.07
Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis (2006) 1.07
Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study. Clin Infect Dis (2005) 1.06
Incidence of vaccine preventable pneumococcal invasive infections and blood culture practices in Italy. Vaccine (2005) 1.03
Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis (2000) 0.97
Health technology assessment and its influence on health-care priority setting. Int J Technol Assess Health Care (2004) 0.90
Pneumococcal vaccination and pneumonia: even a low level of clinical effectiveness is highly cost-effective. Clin Infect Dis (2001) 0.87
The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol (2004) 0.86
Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands. Pharmacoeconomics (2001) 0.86
Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev Vaccines (2003) 0.83
Polysaccharide pneumococcal vaccines. BMJ (2002) 0.82
Simultaneous immunisation with influenza vaccine and pneumococcal polysaccharide vaccine in patients with chronic respiratory disease. BMJ (1997) 0.78
Pneumococcal vaccination by general practitioners: an evaluation of current practice. Vaccine (1999) 0.78
Pneumococcal vaccination of the elderly: do we need another trial? Arch Intern Med (2000) 0.75
Economic evaluations of adult pneumococcal vaccination strategies. Expert Rev Pharmacoecon Outcomes Res (2001) 0.75
[Dutch Health Council advice 'Vaccination against pneumococcal infections in elderly persons and immunocompromised adults']. Ned Tijdschr Geneeskd (2004) 0.75
The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med (2001) 7.49
Intestinal fluid and electrolyte transport in human cholera. J Clin Invest (1970) 3.09
Replacement of water and electrolyte losses in cholera by an oral glucose-electrolyte solution. Ann Intern Med (1969) 2.28
Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries. Vaccine (2003) 2.26
A hospital-based influenza immunization program, 1977-78. Am J Public Health (1983) 2.23
Correlated studies of a recombinant influenza-virus vaccine. 3. Protection against experimental influenza in man. J Infect Dis (1971) 2.13
Cost-effectiveness of universal pneumococcal vaccination for infants in Italy. Vaccine (2005) 2.03
An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. J Clin Microbiol (2000) 1.97
Patient satisfaction with out-of-hours primary care in the Netherlands. BMC Health Serv Res (2005) 1.77
Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA (1997) 1.74
Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia. Eur Respir J (2007) 1.65
Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001-2003. Clin Microbiol Infect (2005) 1.54
Intrathecal baclofen therapy in children with intractable spastic cerebral palsy: a cost-effectiveness analysis. Dev Med Child Neurol (2008) 1.45
Penicillin-resistant Streptococcus pneumoniae in Germany: genetic relationship to clones from other European countries. J Med Microbiol (1995) 1.45
Invasive group A, B, C and G streptococcal infections in Denmark 1999-2002: epidemiological and clinical aspects. Clin Microbiol Infect (2005) 1.42
Influenza and pneumococcal immunization strategies for physicians. Chest (1987) 1.35
Latex assay for serotyping of group B Streptococcus isolates. J Clin Microbiol (2003) 1.33
Previous hospital care as a risk factor for pneumonia. Implications for immunization with pneumococcal vaccine. JAMA (1982) 1.30
Epidemiology of invasive pneumococcal infections in children aged 0-6 years in Denmark: a 19-year nationwide surveillance study. Acta Paediatr Suppl (2000) 1.29
Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patients. J Clin Microbiol (1999) 1.24
Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines. Clin Infect Dis (2000) 1.22
"The old man's friend". Lancet (1993) 1.20
Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol (2009) 1.15
Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in healthy children and in children at increased risk of pneumococcal infection. Vaccine (1995) 1.12
Antibody responses in children and elderly persons following local or parenteral administration of an inactivated influenza virus vaccine, A2-Hong Kong-68 variant. J Immunol (1969) 1.11
The cell wall-associated serine protease PrtA: a highly conserved virulence factor of Streptococcus pneumoniae. FEMS Microbiol Lett (2001) 1.10
Haemorrhagic smallpox. J Hyg (Lond) (1969) 1.09
Systematic review of economic evaluations of smoking cessation: standardizing the cost-effectiveness. Med Decis Making (2005) 1.08
Macrolide resistance in Streptococcus pyogenes isolates from throat infections in the region of Aachen, Germany. Microb Drug Resist (2001) 1.08
Spatially explicit predictions of blood parasites in a widely distributed African rainforest bird. Proc Biol Sci (2010) 1.04
Nationwide German multicenter study on prevalence of antibiotic resistance in staphylococcal bloodstream isolates and comparative in vitro activities of quinupristin-dalfopristin. J Clin Microbiol (2000) 1.04
Acceptance of hepatitis B vaccine by medical and surgical residents. J Gen Intern Med (1988) 1.03
Endophthalmitis due to Microbacterium species: case report and review of microbacterium infections. Clin Infect Dis (1997) 1.02
Anti-neuraminidase antibody response in serum and nasal secretions following intranasal or subcutaneous inactivated A2-Hong Kong-68 influenza virus vaccine. J Immunol (1971) 1.01
Influenza. The continuing need and justification for immunization. Prim Care (1977) 1.00
Antibacterial resistance among children with community-acquired respiratory tract infections (PROTEKT 1999-2000). J Infect (2004) 0.99
Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis (2000) 0.97
False-negative results in typing of group B streptococci by the standard lancefield antigen extraction method. J Clin Microbiol (2002) 0.96
Streptococcus mitis with unusually high level resistance to beta-lactam antibiotics. Microb Drug Resist (1998) 0.95
Comparative evaluation of a new Vitek 2 system for identification and antimicrobial susceptibility testing of Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis (2006) 0.94
Serotype distribution in pneumococcal acute otitis media with ruptured tympanic membrane or sepsis in Germany. Eur J Clin Microbiol Infect Dis (2010) 0.94
Rifabutin for experimental pneumococcal meningitis. Chemotherapy (1997) 0.93
Pneumococcal vaccination: what have we learnt so far and what can we expect in the future? Eur J Clin Microbiol Infect Dis (2014) 0.93
Hospital-based pneumococcal immunization: the epidemiologic rationale and its implementation. Infect Control (1982) 0.92
Indicator dilution studies in the small bowel of patients with cholera diarrhea. II. Comparisons of absorbable and "poorly absorbable" substances. Johns Hopkins Med J (1970) 0.91
Presence of A-Equi-2 hemagglutinin and neuraminidase antibodies in man. Proc Soc Exp Biol Med (1972) 0.91
Antibody responses in serum and nasal secretions according to age of recipient and method of administration of A2-Hong Kong-68 inactivated influenza virus vaccine. J Immunol (1970) 0.91
Epidemiology of invasive Streptococcus pyogenes infections in Germany, 1996-2002: results from a voluntary laboratory surveillance system. Clin Microbiol Infect (2007) 0.89
Hospital-based influenza and pneumococcal vaccination: Sutton's Law applied to prevention. Infect Control Hosp Epidemiol (2000) 0.89
A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma. J Intern Med (2004) 0.89
Increased titers of antibodies against streptococcal M12 and M19 proteins in patients with Tourette's syndrome. Psychiatry Res (2001) 0.88
Influenza and pneumococcal immunization in medical clinics, 1978-1980. Arch Intern Med (1983) 0.88
Bacteremia caused by Stomatococcus mucilaginosus: report of seven cases and review of the literature. Infection (1992) 0.88
Invasive group B streptococcal disease in infants: a 19-year nationwide study. Serotype distribution, incidence and recurrent infection. Epidemiol Infect (2004) 0.88
Previous hospital care and pneumococcal bacteremia. Importance for pneumococcal immunization. Arch Intern Med (1983) 0.87
Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection. Scand J Infect Dis (1998) 0.87
Influenza vaccination in 29 countries. An update to 1997. Pharmacoeconomics (1999) 0.87
Pneumococcal vaccination and pneumonia: even a low level of clinical effectiveness is highly cost-effective. Clin Infect Dis (2001) 0.87
Negligible adjuvant effect for antibody responses and frequent adverse events associated with IL-12 treatment in humans vaccinated with pneumococcal polysaccharide. Vaccine (2001) 0.86
Characteristics of the major etiologic agents of bacterial meningitis isolated in Poland in 1997-1998. Microb Drug Resist (2000) 0.86
Pneumococcal vaccination. Controversies and opportunities. Infect Dis Clin North Am (1990) 0.86
Globicatella sanguinis is an etiological agent of ventriculoperitoneal shunt-associated meningitis. J Clin Microbiol (2006) 0.86
Adult invasive pneumococcal disease between 2003 and 2006 in North-Rhine Westphalia, Germany: serotype distribution before recommendation for general pneumococcal conjugate vaccination for children <2 years of age. Clin Microbiol Infect (2009) 0.85
Global distribution of Streptococcus pneumoniae serotypes isolated from paediatric patients during 1999-2000 and the in vitro efficacy of telithromycin and comparators. J Med Microbiol (2004) 0.85
The ventilatory response to acute base deficit in humans. Time course during development and correction of metabolic acidosis. Ann Intern Med (1970) 0.85
Penicillin-resistant pneumococcus in community-acquired bacteremic pneumonia in Germany. Infection (1992) 0.85
Influenza prevention and control. Past practices and future prospects. Am J Med (1987) 0.84
Distribution of emm types among group A streptococcal isolates from Serbia. Clin Microbiol Infect (2009) 0.84
Influenza vaccination of medical residents at the University of Virginia: 1986 to 1994. Infect Control Hosp Epidemiol (1996) 0.84
Distribution of four capsular serotypes of Enterococcus faecalis among clinical isolates from different geographical origins and infection sites. Infection (2006) 0.84
Blood culture sampling rates at a German pediatric university hospital and incidence of invasive pneumococcal disease. Infection (2004) 0.82
Recurrence of pneumonia in relation to the antibody response after pneumococcal vaccination in middle-aged and elderly adults. Scand J Infect Dis (2000) 0.82
Quinupristin/dalfopristin attenuates the inflammatory response and reduces the concentration of neuron-specific enolase in the cerebrospinal fluid of rabbits with experimental Streptococcus pneumoniae meningitis. J Antimicrob Chemother (1999) 0.82
Japan lagging in influenza jabs. Nature (1996) 0.82
Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy. Clin Exp Rheumatol (2008) 0.81
Overwhelming postsplenectomy infection with vaccine-type Streptococcus pneumoniae in a 12-year-old girl despite vaccination and antibiotic prophylaxis. Infection (1998) 0.81
Asplenic patients' knowledge of prophylactic measures against severe infections. Clin Infect Dis (1997) 0.81
Indicator dilution studies in the small bowel of patients with cholera diarrhea. I. Jejunal flow--transit time--volume relationships. Johns Hopkins Med J (1970) 0.81
Penicillin susceptibility breakpoints for Streptococcus pneumoniae and their effect on susceptibility categorisation in Germany (1997-2013). Eur J Clin Microbiol Infect Dis (2014) 0.81
Release of teichoic and lipoteichoic acids from 30 different strains of Streptococcus pneumoniae during exposure to ceftriaxone, meropenem, quinupristin/dalfopristin, rifampicin and trovafloxacin. Infection (2000) 0.80
The need for revaccination 10 years after primary pneumococcal vaccination in splenectomized adults. Scand J Infect Dis (1991) 0.80
Relation of ventilation during base deficit to acid-base values in blood and spinal fluid. J Appl Physiol (1971) 0.79
Improving the use of pneumococcal vaccine through a strategy of hospital-based immunization: a review of its rationale and implications. J Am Geriatr Soc (1985) 0.79
Hospital care and pneumococcal immunisation policy. Lancet (1982) 0.79
In vitro activity of gatifloxacin against Streptococcus pneumoniae isolates in Germany. J Antimicrob Chemother (2000) 0.79
Antibiotic sensitivity of Streptococcus pneumoniae isolated from normally sterile body sites: first results of a multicenter study in Germany. Infection (1994) 0.78
Intractable spastic cerebral palsy in children: a Dutch cost of illness study. Dev Med Child Neurol (2007) 0.78
Adult immunization: protocols and problems. Hosp Pract (Off Ed) (1986) 0.78
Pneumococcal vaccine and HIV-1 infection. Lancet (2000) 0.78
[Group B streptococcal infection in adults]. Ugeskr Laeger (1997) 0.78
Net and unidirectional transmucosal flux of sodium and water in acute human diarrheal disease. J Lab Clin Med (1972) 0.78
Restoring balance to internal medicine training: the case for the teaching office practice. Am J Med Sci (1990) 0.78
Prospects for broad-spectrum chemotherapy of serious viral respiratory infections. JAMA (1983) 0.78
Evaluation of gastrointestinal symptoms as primary sign of severe invasive group A streptococcal infections. Indian J Med Res (2004) 0.77
Reminding and monitoring: new uses of administrative data for preventive care. Healthc Manage Forum (1996) 0.75
Streptococcus acidominimus in a case of bovine fibrinopurulent metritis. Can Vet J (1998) 0.75
Use of pneumococcal vaccine. J Gen Intern Med (1995) 0.75
Activity of fosfomycin in a rabbit model of experimental pneumococcal meningitis. J Antimicrob Chemother (1995) 0.75
Risk factor analysis for pneumococcal meningitis in adults with invasive pneumococcal infection. Epidemiol Infect (2010) 0.75